Dec 21 (Reuters) - AstraZeneca Plc (AZN.L) said on Tuesday it is working with Oxford University to produce a vaccine for the Omicron coronavirus variant, joining other vaccine-makers who are looking to develop the variant-specific vaccine. "Together with Oxford University, we have taken preliminary steps in producing an Omicron variant vaccine, in case it is needed and will be informed by emerging data," a spokesperson for the company said in a statement. Oxford did not immediately respond to a request for comment outside business hours. The Financial Times first reported the news, citing Sandy Douglas, a research group leader at Oxford. "Adenovirus-based vaccines (such as that made by Oxford/AstraZeneca) could in principle be used to respond to any new variant more rapidly than some may previously have realised," Douglas told FT. A lab-study last week found that AstraZeneca"s antibody cocktail Evusheld retained neutralising activity against the Omicron variant. read more Vaccine makers Pfizer/BioNTech (PFE.N), (22UAy.DE) and Moderna (MRNA.O) also previously said they were working on Omicron- specific COVID-19 vaccines. Moderna said hopes to start clinical trials early next year.